Tailored therapy guided by genotypic resistance of clarithromycin and levofloxacin detected by polymerase chain reaction in the first‐line treatment of Helicobacter pylori infection
Journal of Digestive Diseases · 2024
DOI: 10.1111/1751-2980.13250 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Digestive Diseases, 2024. Verfasst von Cai Ling Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Youth Incubation Fund of Peking University Third Hospital, National Natural Science Foundation of China, Capital's Funds for Health Improvement and Research.
Abstract (Originalsprache)
Objectives
We aimed to explore the efficacy and safety of tailored therapy guided by genotypic resistance in the first‐line treatment of Helicobacter pylori ( H. pylori ) infection in treatment‐naive patients.
Methods
Gastric mucosal specimens were taken during gastroscopy, and main mutations of clarithromycin‐ and levofloxacin‐resistant genes were detected by polymerase chain reaction (PCR). Sensitive antibiotics were selected individually for treating H. pylori infection with tailored bismuth‐containing quadruple therapy (BQT) consisting of esomeprazole 20 mg twice daily, bismuth potassium citrate 220 mg twice daily, amoxicillin 1 g twice daily, and clarithromycin 500 mg twice daily, or levofloxacin 500 mg once daily, or metronidazole 400 mg four times daily. Safety and patient compliance were assessed 1–3 days after eradication. Treatment outcome was evaluated by urea breath test 4–8 weeks after eradication.
Results
One hundred and thirty‐two treatment‐naive patients with H. pylori infection were included. PCR results suggested resistance rates of 47.7% and 34.9% for clarithromycin and levofloxacin, respectively, and a dual resistance rate of 18.2%. Eradication rates of tailored BQT were 87.1% and 95.8% by intention‐to‐treat (ITT) analysis and per‐protocol (PP) analysis, respectively. There was no statistically significant difference in the efficacy of 7‐day clarithromycin‐containing, 7‐day levofloxacin‐containing, and 14‐day full‐dose metronidazole‐containing BQT (ITT analysis: P = 0.488; PP analysis: P = 0.833). The incidence of adverse events was 19.7%, and patient compliance was 97.7%.
Conclusion
Tailored BQT guided by genotypic resistance can achieve satisfactory efficacy, safety, and patient compliance in the first‐line treatment of H. pylori infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Peking University Third Hospital, Beijing, China.
- Department of Gastroenterology, Beijing No. 6 Hospital, Beijing, China.
- Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.
ORCID-Profile: Cai Ling Li, Kai Zhou
Förderung
- Youth Incubation Fund of Peking University Third Hospital
- National Natural Science Foundation of China
- Capital's Funds for Health Improvement and Research
- Beijing Municipal Natural Science Foundation
- Key Laboratory for Helicobacter pylori Infection and Upper Gastrointestinal Diseases in Beijing
Zitieren
APA
Li, C. L., Zhou, K., Zhang, Y. X., Suo, B. J., Tian, X. L., Zhang, Y. X., Ren, X. L., Shi, Y. Y., Zhou, L. Y., & Song, Z. Q. (2024). Tailored therapy guided by genotypic resistance of clarithromycin and levofloxacin detected by polymerase chain reaction in the first‐line treatment of Helicobacter pylori infection. Journal of Digestive Diseases. https://doi.org/10.1111/1751-2980.13250
Vancouver
Li CL, Zhou K, Zhang YX, Suo BJ, Tian XL, Zhang YX, et al. Tailored therapy guided by genotypic resistance of clarithromycin and levofloxacin detected by polymerase chain reaction in the first‐line treatment of Helicobacter pylori infection. Journal of Digestive Diseases. 2024. doi:10.1111/1751-2980.13250
BibTeX
@article{Li2024,
author = {Li, Cai Ling and Zhou, Kai and Zhang, Yue Xi and Suo, Bao Jun and Tian, Xue Li and Zhang, Yu Xin and Ren, Xin Lu and Shi, Yan Yan and Zhou, Li Ya and Song, Zhi Qiang},
title = {Tailored therapy guided by genotypic resistance of clarithromycin and levofloxacin detected by polymerase chain reaction in the first‐line treatment of Helicobacter pylori infection},
journal = {Journal of Digestive Diseases},
year = {2024},
doi = {10.1111/1751-2980.13250}
}
EUVIMED